4D Pharma, a leading research-based company involved in the development of Live Biotherapeutics such as biological products that contain live organisms such as a bacterium for treating diseases, said its new oral asthma drug candidate – MRx-4DP0004 – generated promising signals of clinical activity. Announcing the trial results, the company said  the Part A of phase I/II clinical trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma, met the primary endpoint of safety and tolerability and has also achieved multiple key secondary endpoints relating to improved asthma control compared to placebo. These results support the trial progression into Part B of the study, which is expected to enrol 90 participants, the company said. The Part A trial was a multicenter, double-blind, placebo-controlled study in patients with partly controlled asthma taking long-term medication.